653 results on '"Röth, Alexander"'
Search Results
2. Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
3. Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
4. Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
5. Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension
6. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
7. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study
8. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
9. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
10. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
11. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
12. Population Pharmacokinetic/Pharmacodynamic Modeling and Simulation of a Flat Quarterly Riliprubart Dosing Regimen for Patients With Cold Agglutinin Disease
13. Crizanlizumab in adult patients with sickle cell disease: a retrospective German analysis
14. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
15. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial
16. Screening and diagnosis of hemoglobinopathies in Germany: Current state and future perspectives
17. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
18. Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial
19. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
20. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial
21. Safety, tolerability and activity of the active C1s antibody riliprubart in cold agglutinin disease: A Phase 1b study
22. Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity
23. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry
24. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease
25. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
26. Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity.
27. Long‐term effectiveness of eculizumab: Data from the International PNH Registry
28. MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size With Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients
29. MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
30. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
31. POSTER: MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size With Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients
32. POSTER: MDS-273 Oral Iptacopan Monotherapy Increases Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size Via Control of Intra- and Extravascular Hemolysis in Anti-C5-Treated PNH Patients With Anemia
33. 26 Sustained complement C1s inhibition with sutimlimab in patients with cold agglutinin disease results in continued efficacy during part B of the randomized placebo-controlled phase 3 CADENZA study (NCT03347422)
34. P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
35. P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY
36. P1474: HEMOLYTIC MARKERS, MORTALITY, AND THROMBOEMBOLIC EVENTS IN CAD: RISK ASSESSMENT BY TIME PERIOD SINCE DIAGNOSIS
37. S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
38. P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
39. PB2043: CLINICAL EFFECTIVENESS, TREATMENT USE, SATISFACTION AND IMPACT ON QUALITY-OF-LIFE OF PEGCETACOPLAN TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH).
40. P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY
41. P1487: CONCOMITANT USE OF SUTIMLIMAB AND COVID-19 VACCINES IN PATIENTS WITH COLD AGGLUTININ DISEASE FROM THE PHASE 3 CARDINAL AND CADENZA STUDIES
42. P1675: SUTIMLIMAB PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: OPEN-LABEL EXTENSION OF THE PHASE 3 CADENZA STUDY
43. P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH.
44. S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS
45. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies
46. Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)—a report on phase III
47. Plain language summary of PEGASUS, a study comparing pegcetacoplan with eculizumab for 16 weeks in people with paroxysmal nocturnal hemoglobinuria
48. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease
49. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double‐blind, placebo‐controlled, global study (FORWARD).
50. Long‐term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real‐world setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.